00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
07:00 , Mar 30, 2015 |  BioCentury  |  Emerging Company Profile

Effusion dissolution

Lung Therapeutics Inc. is developing therapies that prevent or resolve fibrosis to treat Orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Tenecteplase: Phase II data

Researchers at the University of Glasgow reported data from the open-label, U.K. Phase II ATTEST trial in 104 patients with supratentorial ischemic stroke showing that there was no significant difference between IV tenecteplase and...
08:00 , Dec 11, 2014 |  BC Innovations  |  Targets & Mechanisms

Terazosin reborn

In searching for compounds to treat stroke or sepsis, a Chinese team has found a new activity-and possibly a new indication-for an old drug. Terazosin, a generic a-blocker used in hypertension, inhibited apoptosis and extended...
08:00 , Jan 20, 2014 |  BioCentury  |  Emerging Company Profile

Zocere: Stepping up in stroke

Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP protein that could improve patient outcomes...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Activase alteplase: Phase III data

Roche's Genentech Inc. unit markets alteplase in the U.S. as Activase to treat acute ischemic stroke within 3 hours after stroke symptom onset and after exclusion of intracranial hemorrhage, for acute myocardial infarction (MI) and...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Alteplase regulatory update

Kyowa and Mitsubishi Tanabe said Japan's Ministry of Health, Labor and Welfare (MHLW) approved the use of Activacin/ GRTPA alteplase within 4.5 hours of the onset of symptoms of acute ischemic cerebrovascular disease. Previously,...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Clinical News

Activase regulatory update

The U.K.'s NICE issued final guidance recommending the use of Actilyse alteplase to treat acute ischemic stroke. Specifically, the guidance recommends the use of Actilyse within 4.5 hours of the onset of symptoms after intracranial...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

Activase regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) to update its previous recommendation on the use of Actilyse alteplase to treat acute ischemic stroke. Specifically, the guidance recommends the use of Actilyse within 4.5...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

Alteplase regulatory update

Roche disclosed in its 2Q12 earnings that it withdrew an sBLA to expand the label for Activase alteplase to extend the time window for treatment of acute ischemic stroke (AIS) to 4.5 hours. Activase...